BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 20, 2002
View Archived Issues
Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia
The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)
Read More
ICOS Drops Pafase After Interim Analysis Of Phase III Sepsis Trial
Read More
Luciferase Probe Sees Real-Time Imaging Of Apoptosis In Drug's Performance - Noninvasively
Read More
Genentech, Tanox, Novartis Finalize Application For Xolair
Read More
Pharmacyclics Steps Back Up With Pivotal Study Of Xcytrin
Read More
Other News To Note
Read More